Nonplatelet mechanisms may have a role in these events; therefore, other drugs have been tested. Warfarin sodium has been used among patients with ACS in combination with aspirin vs aspirin alone, showing a significant decrease in recurrent events but also a significant increase in major bleeding events with the combined treatment.2
In contrast to warfarin, novel oral anticoagulants (NOACs), such as direct thrombin inhibitors and anti-Xa, do not require monitoring and have minimal food and drug interactions. Moreover, compared with warfarin NOACs have demonstrated significant reductions in thrombotic events and lower rates of major bleeding events in patients having atrial fibrillation and in patients undergoing knee and hip surgery.3 In recent years, several phase 2 and phase 3 trials of NOACs for the treatment of patients with ACS have been published, with most of the patients receiving dual antiplatelet treatment. Although recent detailed review articles have described the pros and cons of the use of NOACs in ACS,4,5 the available evidence has not been quantitatively summarized.
Thank you for submitting a comment on this article. It will be reviewed by JAMA Internal Medicine editors. You will be notified when your comment has been published. Comments should not exceed 500 words of text and 10 references.
Do not submit personal medical questions or information that could identify a specific patient, questions about a particular case, or general inquiries to an author. Only content that has not been published, posted, or submitted elsewhere should be submitted. By submitting this Comment, you and any coauthors transfer copyright to the journal if your Comment is posted.
* = Required Field
Disclosure of Any Conflicts of Interest*
Indicate all relevant conflicts of interest of each author below, including all relevant financial interests, activities, and relationships within the past 3 years including, but not limited to, employment, affiliation, grants or funding, consultancies, honoraria or payment, speakers’ bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued. If all authors have none, check "No potential conflicts or relevant financial interests" in the box below. Please also indicate any funding received in support of this work. The information will be posted with your response.
Some tools below are only available to our subscribers or users with an online account.
Download citation file:
Web of Science® Times Cited: 3
Customize your page view by dragging & repositioning the boxes below.
More Listings atJAMACareerCenter.com >
The Rational Clinical Examination
Evidence Summary and Review 2
The Rational Clinical Examination
Multivariate Findings for ACI Syndromes
All results at
Enter your username and email address. We'll send you a link to reset your password.
Enter your username and email address. We'll send instructions on how to reset your password to the email address we have on record.
Athens and Shibboleth are access management services that provide single sign-on to protected resources. They replace the multiple user names and passwords necessary to access subscription-based content with a single user name and password that can be entered once per session. It operates independently of a user's location or IP address. If your institution uses Athens or Shibboleth authentication, please contact your site administrator to receive your user name and password.